{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T09:30:50Z","timestamp":1794562250671,"version":"4.9.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ajo.2026.05.028","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T06:50:33Z","timestamp":1779432633000},"page":"87-96","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Clinical Features of Corneal Adverse Events Associated With Trastuzumab Botidotin: Payload-Driven Epitheliopathy and Neuropathy"],"prefix":"10.1016","volume":"289","author":[{"given":"Yongyi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gege","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinghao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhua","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1433-375X","authenticated-orcid":false,"given":"Nan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"46","key":"10.1016\/j.ajo.2026.05.028_bib0001","doi-asserted-by":"crossref","first-page":"6577","DOI":"10.1038\/sj.onc.1210478","article-title":"Targeting the function of the HER2 oncogene in human cancer therapeutics","volume":"26","author":"Moasser","year":"2007","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.ajo.2026.05.028_bib0002","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/path.4987","article-title":"A new model system identifies epidermal growth factor receptor-human epidermal growth factor receptor 2 (HER2) and HER2-human epidermal growth factor receptor 3 heterodimers as potent inducers of oesophageal epithelial cell invasion","volume":"243","author":"Fichter","year":"2017","journal-title":"J Pathol"},{"issue":"45","key":"10.1016\/j.ajo.2026.05.028_bib0003","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1038\/sj.onc.1210477","article-title":"The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis","volume":"26","author":"Moasser","year":"2007","journal-title":"Oncogene"},{"issue":"6220","key":"10.1016\/j.ajo.2026.05.028_bib0004","doi-asserted-by":"crossref","DOI":"10.1126\/science.1260419","article-title":"Proteomics. tissue-based map of the human proteome","volume":"347","author":"Uhl\u00e9n","year":"2015","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.ajo.2026.05.028_bib0005","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody-drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"10.1016\/j.ajo.2026.05.028_bib0006","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41408-021-00494-4","article-title":"Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)","volume":"11","author":"Lonial","year":"2021","journal-title":"Blood Cancer J"},{"issue":"23","key":"10.1016\/j.ajo.2026.05.028_bib0007","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab soravtansine in FR\u03b1-positive, platinum-resistant ovarian cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ajo.2026.05.028_bib0008","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(21)00056-5","article-title":"Efficacy and Safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204\/GOG-3023\/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Coleman","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ajo.2026.05.028_bib0009","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41523-023-00522-5","article-title":"Phase I study of A166, an antibody\u2012drug conjugate in advanced HER2-expressing solid tumours","volume":"9","author":"Zhang","year":"2023","journal-title":"NPJ Breast Cancer"},{"issue":"3","key":"10.1016\/j.ajo.2026.05.028_bib0010","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jtos.2017.05.008","article-title":"TFOS DEWS II definition and classification report","volume":"15","author":"Craig","year":"2017","journal-title":"Ocul Surf"},{"issue":"1","key":"10.1016\/j.ajo.2026.05.028_bib0011","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1001\/jamaophthalmol.2025.3159","article-title":"Multicenter interspecialty consensus on experimental oncology drug-related ocular adverse event reporting","volume":"144","author":"Pasricha","year":"2026","journal-title":"JAMA Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2026.05.028_bib0012","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jtos.2017.05.001","article-title":"TFOS DEWS II diagnostic methodology report","volume":"15","author":"Wolffsohn","year":"2017","journal-title":"Ocul Surf"},{"issue":"11","key":"10.1016\/j.ajo.2026.05.028_bib0013","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyae177","article-title":"Ocular adverse events associated with antibody-drug conjugates for cancer: evidence and management strategies","volume":"29","author":"Dy","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.ajo.2026.05.028_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2024.101302","article-title":"Ocular adverse events associated with antibody-drug conjugates used in cancer: focus on pathophysiology and management strategies","volume":"103","author":"Gabison","year":"2024","journal-title":"Prog Retin Eye Res"},{"issue":"4","key":"10.1016\/j.ajo.2026.05.028_bib0015","doi-asserted-by":"crossref","first-page":"391","DOI":"10.4252\/wjsc.v6.i4.391","article-title":"Limbal stem cells: central concepts of corneal epithelial homeostasis","volume":"6","author":"Yoon","year":"2014","journal-title":"World J Stem Cells"},{"issue":"2","key":"10.1016\/j.ajo.2026.05.028_bib0016","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s10549-019-05179-y","article-title":"Corneal features in trastuzumab emtansine treatment: not a rare occurrence","volume":"175","author":"Deklerck","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.ajo.2026.05.028_bib0017","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s13045-021-01172-5","article-title":"Corneal in vivo confocal microscopy to detect belantamab mafodotin-induced ocular toxicity early and adjust the dose accordingly: a case report","volume":"14","author":"Marquant","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ajo.2026.05.028_bib0018","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ajo.2022.06.009","article-title":"Corneal toxicity associated with belantamab mafodotin is not restricted to the epithelium: neuropathy studied with confocal microscopy","volume":"242","author":"Aschauer","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2026.05.028_bib0019","article-title":"Acute keratoconjunctivitis associated with tisotumab vedotin-tftv for metastatic cervical cancer","volume":"33","author":"Parikh","year":"2024","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"10","key":"10.1016\/j.ajo.2026.05.028_bib0020","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.3390\/jcm11102884","article-title":"Corneal findings associated to belantamab-mafodotin (belamaf) use in a series of patients examined longitudinally by means of advanced corneal imaging","volume":"11","author":"Mencucci","year":"2022","journal-title":"J Clin Med"},{"issue":"6","key":"10.1016\/j.ajo.2026.05.028_bib0021","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1097\/ICO.0000000000001560","article-title":"Confocal microscopy observation of cornea verticillata after vandetanib therapy for medullary thyroid carcinoma","volume":"37","author":"Arriola-Villalobos","year":"2018","journal-title":"Cornea"},{"issue":"3","key":"10.1016\/j.ajo.2026.05.028_bib0022","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.survophthal.2016.11.008","article-title":"Drug-induced corneal epithelial changes","volume":"62","author":"Raizman","year":"2017","journal-title":"Surv Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2026.05.028_bib0023","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1002\/cam4.2066","article-title":"Antitumor activity of a 5T4 targeting antibody drug conjugate with a novel payload derived from MMAF via C-lock linker","volume":"8","author":"Shi","year":"2019","journal-title":"Cancer Med"},{"issue":"10","key":"10.1016\/j.ajo.2026.05.028_bib0024","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1089\/jop.2015.0064","article-title":"Ocular adverse events associated with antibody-drug conjugates in human clinical trials","volume":"31","author":"Eaton","year":"2015","journal-title":"J Ocul Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.ajo.2026.05.028_bib0025","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/cyto.a.10068","article-title":"Staurosporine-induced apoptosis in human cornea epithelial cells in vitro","volume":"55","author":"H\u00e4rtel","year":"2003","journal-title":"Cytometry A"},{"issue":"9","key":"10.1016\/j.ajo.2026.05.028_bib0026","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1097\/ICO.0000000000002595","article-title":"Clinical and histological characterization of toxic keratopathy from depatuxizumab mafodotin (ABT-414), an antibody-drug conjugate","volume":"40","author":"Lee","year":"2021","journal-title":"Cornea"},{"issue":"1","key":"10.1016\/j.ajo.2026.05.028_bib0027","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1038\/s41598-021-81398-y","article-title":"A cross-sectional study of ocular surface discomfort and corneal nerve dysfunction after paclitaxel treatment for cancer","volume":"11","author":"Chiang","year":"2021","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.ajo.2026.05.028_bib0028","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1167\/iovs.66.4.40","article-title":"Corneal sensory nerve injury disrupts lacrimal gland function by altering circadian rhythms in mice","volume":"66","author":"Li","year":"2025","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939426002746?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939426002746?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T09:17:31Z","timestamp":1794561451000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939426002746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":28,"alternative-id":["S0002939426002746"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2026.05.028","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Features of Corneal Adverse Events Associated With Trastuzumab Botidotin: Payload-Driven Epitheliopathy and Neuropathy","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2026.05.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}